Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151085 | 0.93 | MEN1 (0.58) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL5154471 | 0.90 | MEN1 (0.61) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL29829593 | 0.83 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21581235 | 0.83 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14030437 | 0.82 | MEN1 (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL15906301 | 0.82 | MEN1 (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL5150796 | 0.81 | MEN1 (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL29358957 | 0.80 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL29379210 | 0.80 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL6758944 | 0.77 | HSPA8 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | PDE4A 429/4885PDE4B 567/4885PDE4C 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.